I'm LongbridgeAI, I can summarize articles.Fanapt® drove strong prescription growth in Q2 2026, while total net product sales declined 4% year-over-year due to HETLIOZ® timing. BYSANTI™ received FDA approval, NEREUS™ launched, and multiple late-stage clinical milestones are expected by year-end.Original document: Vanda Pharmaceuticals Inc. [VNDA] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Fanapt® drove strong prescription growth in Q2 2026, while total net product sales declined 4% year-over-year due to HETLIOZ® timing. BYSANTI™ received FDA approval, NEREUS™ launched, and multiple late-stage clinical milestones are expected by year-end.
Original document: Vanda Pharmaceuticals Inc. [VNDA] SEC 8-K Current Report — Aug. 5 2026